ReqMed Overview
- Year Founded
-
1998
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
IPO
- (Cancelled)
- Latest Deal Amount
-
$9.4M
- Investors
-
9
ReqMed General Information
Description
ReqMed Co Ltd focuses on developing treatments for unmet medical needs. It conducts clinical development activities, obtains regulatory approvals for manufacturing and sales, and commercializes its pharmaceutical products to patients.
Contact Information
Website
www.reqmed.co.jpCorporate Office
- 2nd Floor, Taiju Life Machida Building
- 1-7-23 Morino, Machida
- Tokyo, 194-0022
- Japan
Corporate Office
- 2nd Floor, Taiju Life Machida Building
- 1-7-23 Morino, Machida
- Tokyo, 194-0022
- Japan
ReqMed Timeline
ReqMed Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. IPO | 02-Apr-2026 | $9.4M | Cancelled | Generating Revenue | ||
| 3. Later Stage VC | 16-Jun-2025 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 01-Dec-2023 | Completed | Generating Revenue | |||
| 1. Later Stage VC | 01-Dec-2020 | Completed | Generating Revenue |
ReqMed Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class A Shares |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ReqMed Patents
ReqMed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-6935960-B2 | New pentosan polysulfate sodium preparation | Active | 20-Aug-2018 | ||
| JP-WO2020039480-A1 | New pentosan polysulfate sodium preparation | Active | 20-Aug-2018 | ||
| AU-2018437600-A1 | Novel pentosan polysulfate sodium preparation | Active | 20-Aug-2018 | ||
| AU-2018437600-B2 | Novel pentosan polysulfate sodium preparation | Active | 20-Aug-2018 | ||
| EP-3842048-A1 | Novel pentosan polysulfate sodium preparation | Active | 20-Aug-2018 | A61K47/02 |
ReqMed Signals
ReqMed Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Okasan Securities Group | Holding Company | Minority | ||
| Yokohama Capital | Venture Capital | Minority | ||
| CEJ Capital | Corporate Venture Capital | Minority | ||
| Cyberdyne | Corporation | Minority | ||
| Edge Labs | Venture Capital | Minority |
ReqMed Investments (1)
ReqMed’s most recent deal was a Later Stage VC with Ansaris for . The deal was made on 28-Nov-2000.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ansaris | 28-Nov-2000 | Later Stage VC | Drug Discovery |
ReqMed FAQs
-
When was ReqMed founded?
ReqMed was founded in 1998.
-
Where is ReqMed headquartered?
ReqMed is headquartered in Tokyo, Japan.
-
What is the size of ReqMed?
ReqMed has 22 total employees.
-
What industry is ReqMed in?
ReqMed’s primary industry is Other Healthcare Services.
-
Is ReqMed a private or public company?
ReqMed is a Private company.
-
What is the current valuation of ReqMed?
The current valuation of ReqMed is .
-
What is ReqMed’s current revenue?
The current revenue for ReqMed is .
-
How much funding has ReqMed raised over time?
ReqMed has raised $9M.
-
Who are ReqMed’s investors?
Okasan Securities Group, Yokohama Capital, CEJ Capital, Cyberdyne, and Edge Labs are 5 of 9 investors who have invested in ReqMed.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process